US Stock MarketDetailed Quotes
XLO Xilio Therapeutics
- 1.150
- -0.130-10.16%
Close Apr 19 16:00 ET
- 1.181
- +0.031+2.65%
Post 19:57 ET
39.64MMarket Cap-413P/E (TTM)
1.280High1.120Low339.70KVolume1.250Open1.280Pre Close403.36KTurnover2.07%Turnover RatioLossP/E (Static)34.47MShares3.40052wk High1.08P/B18.90MFloat Cap0.49052wk Low--Dividend TTM16.44MShs Float27.950Historical High--Div YieldTTM12.50%Amplitude0.490Historical Low1.187Avg Price1Lot Size
Xilio Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 9.38%-68.62M | 26.32%-13.43M | 32.85%-13.37M | 1.09%-16.57M | -21.19%-25.25M | 6.23%-75.72M | -6.18%-18.22M | 3.91%-19.91M | 16.79%-16.76M | 8.35%-20.84M |
| Net income from continuing operations | 13.40%-76.4M | 21.41%-17.66M | 15.37%-16.75M | 21.36%-19.36M | -6.06%-22.65M | -16.39%-88.22M | -14.03%-22.47M | -21.78%-19.79M | -6.18%-24.61M | -28.12%-21.35M |
| Operating gains losses | 200.00%3K | --0 | --1K | ---- | ---- | -99.55%1K | --0 | ---- | ---- | ---- |
| Depreciation and amortization | 2.87%1.9M | -8.18%449K | -2.75%460K | 10.56%492K | 13.41%499K | 23.22%1.85M | 24.11%489K | 23.82%473K | 19.30%445K | 25.71%440K |
| Other non cash items | -29.60%157K | -72.88%16K | -60.34%23K | 64.15%87K | -41.51%31K | 28.90%223K | 13.46%59K | 34.88%58K | 32.50%53K | 39.47%53K |
| Change In working capital | -182.73%-1.66M | -2.50%1.83M | 141.00%1.03M | -91.40%400K | -145.76%-4.93M | 116.98%2M | 10,344.44%1.88M | 58.92%-2.52M | 193.93%4.65M | 72.41%-2M |
| -Change in prepaid assets | 100.00%688K | 236.85%1.29M | -491.08%-1.67M | 27.26%663K | 20.83%406K | 110.97%344K | -303.69%-939K | 119.37%426K | 133.59%521K | 119.61%336K |
| -Change in payables and accrued expense | -191.21%-1.89M | -77.27%665K | 199.12%2.82M | -103.42%-145K | -132.58%-5.23M | 124.54%2.07M | 936.00%2.93M | 26.10%-2.84M | 31.21%4.23M | 69.90%-2.25M |
| -Change in other current assets | 17.65%460K | 18.45%122K | 17.00%117K | 17.71%113K | 17.39%108K | 17.77%391K | 17.05%103K | 17.65%100K | 18.52%96K | 17.95%92K |
| -Change in other current liabilities | -14.61%-918K | -13.81%-239K | -14.63%-235K | -14.93%-231K | -15.14%-213K | -42.02%-801K | -16.02%-210K | -15.17%-205K | -14.86%-201K | -516.67%-185K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 9.38%-68.62M | 26.32%-13.43M | 32.85%-13.37M | 1.09%-16.57M | -21.19%-25.25M | 6.23%-75.72M | -6.18%-18.22M | 3.91%-19.91M | 16.79%-16.76M | 8.35%-20.84M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 73.97%-486K | 0 | 0 | 59.01%-316K | 33.07%-170K | -69.73%-1.87M | -34.66%-509K | -192.11%-333K | -76.03%-771K | -49.41%-254K |
| Net PPE purchase and sale | 73.97%-486K | --0 | --0 | 59.01%-316K | 33.07%-170K | -69.73%-1.87M | -34.66%-509K | -192.11%-333K | -76.03%-771K | -49.41%-254K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 73.97%-486K | --0 | --0 | 59.01%-316K | 33.07%-170K | -69.73%-1.87M | -34.66%-509K | -192.11%-333K | -76.03%-771K | -49.41%-254K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -9,392.75%-6.55M | -7,680.95%-1.63M | -10,063.64%-2.24M | -4,623.81%-992K | -33,660.00%-1.69M | -100.03%-69K | -100.02%-21K | -107.31%-22K | 93.98%-21K | -100.00%-5K |
| Net issuance payments of debt | -7,843.53%-6.75M | -7,938.10%-1.69M | -10,100.00%-2.24M | -5,290.48%-1.13M | -7,938.10%-1.69M | 22.73%-85K | 4.55%-21K | -107.67%-22K | 94.07%-21K | 0.00%-21K |
| Proceeds from stock option exercised by employees | 1,162.50%202K | --54K | --8K | --140K | --0 | -94.35%16K | --0 | --0 | --0 | -36.00%16K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -9,392.75%-6.55M | -7,680.95%-1.63M | -10,063.64%-2.24M | -4,623.81%-992K | -33,660.00%-1.69M | -100.03%-69K | -100.02%-21K | -107.31%-22K | 93.98%-21K | -100.00%-5K |
| Net cash flow | ||||||||||
| Beginning cash position | -38.91%121.95M | -56.40%61.35M | -52.19%76.96M | -46.87%94.84M | -38.91%121.95M | 860.15%199.61M | 38.87%140.7M | 32.10%160.96M | 25.03%178.51M | 860.15%199.61M |
| Current changes in cash | 2.58%-75.66M | 19.69%-15.06M | 22.99%-15.61M | -1.90%-17.88M | -28.51%-27.11M | -143.43%-77.66M | -119.08%-18.75M | 1.31%-20.26M | 16.13%-17.55M | -117.29%-21.09M |
| End cash Position | -62.04%46.29M | -62.04%46.29M | -56.40%61.35M | -52.19%76.96M | -46.87%94.84M | -38.91%121.95M | -38.91%121.95M | 38.87%140.7M | 32.10%160.96M | 25.03%178.51M |
| Free cash flow | 10.93%-69.11M | 28.32%-13.43M | 33.95%-13.37M | 3.63%-16.89M | -20.54%-25.42M | 5.21%-77.59M | -6.80%-18.73M | 2.84%-20.24M | 14.81%-17.53M | 7.92%-21.09M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg